Zimmer Biomet (NYSE:ZBH) had its target price increased by equities researchers at SVB Leerink from $185.00 to $190.00 in a report released on Monday, The Fly reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. SVB Leerink’s price objective would indicate a potential upside of 19.38% from the company’s current price. SVB Leerink also issued estimates for Zimmer Biomet’s Q2 2021 earnings at $1.77 EPS, Q4 2021 earnings at $2.42 EPS and FY2021 earnings at $7.82 EPS.
A number of other research analysts have also commented on ZBH. Oppenheimer assumed coverage on Zimmer Biomet in a report on Friday, February 5th. They issued a “buy” rating and a $173.00 price objective on the stock. Credit Suisse Group upped their price objective on Zimmer Biomet from $99.00 to $106.00 and gave the company an “underperform” rating in a report on Monday, November 9th. Argus upped their price objective on Zimmer Biomet from $160.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, December 24th. Raymond James reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Zimmer Biomet in a report on Thursday, December 24th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Zimmer Biomet from $146.00 to $160.00 and gave the company a “hold” rating in a report on Monday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $165.26.
ZBH stock opened at $159.15 on Monday. The company has a current ratio of 2.18, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $32.99 billion, a PE ratio of 994.75, a PEG ratio of 4.32 and a beta of 1.34. Zimmer Biomet has a 1-year low of $74.37 and a 1-year high of $170.05. The business’s 50 day simple moving average is $156.89 and its 200 day simple moving average is $145.36.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 4th. The medical equipment provider reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $2.06 by $0.05. Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.08 billion. During the same period in the prior year, the firm posted $2.30 EPS. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. As a group, sell-side analysts predict that Zimmer Biomet will post 4.8 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Crewe Advisors LLC lifted its position in shares of Zimmer Biomet by 65.0% during the 3rd quarter. Crewe Advisors LLC now owns 198 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 78 shares during the last quarter. Birchcreek Wealth Management LLC bought a new position in Zimmer Biomet in the fourth quarter valued at about $30,000. Exchange Traded Concepts LLC bought a new position in Zimmer Biomet in the fourth quarter valued at about $31,000. CX Institutional raised its position in Zimmer Biomet by 93.9% in the fourth quarter. CX Institutional now owns 223 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 108 shares during the last quarter. Finally, Magellan Asset Management Ltd bought a new position in Zimmer Biomet in the third quarter valued at about $35,000. Institutional investors and hedge funds own 87.17% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.